Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2000-11-30
2003-05-20
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S653000, C514S277000, C514S849000, C514S850000, C424S464000
Reexamination Certificate
active
06566396
ABSTRACT:
FIELD OF INVENTION
The invention relates to novel antitussive and antihistaminic tannate compositions. The compositions contain as essential ingredients carbetapentane tannate and chlorpheniramine tannate.
BACKGROUND OF INVENTION
A considerable number of tannic acids occur in nature. Chemically, these acids are described as polymers of different hydroxybenzoic acids. Generally, when the term tannic acid is employed, as in the present case, the acid referred to is gallotannic acid, the internal ester of gallic acid also frequently referred to as tannin.
Tannic Acid consists of an amorphous powder glistening scales or spongy masses varying in color from yellowish-white to light brown. Tannic acid is very soluble in water, glycerine or alcohol.
Tannic acids are usually obtained from glycosides which consist of several molecules of a tannic acid in combination with glucose.
Commercially available, tannic acid, also known as Tannin, has a complex non-uniform chemistry usually contains from about 5% to about 10% by weight water, has a molecular weight of about 1700 and is typically produced from Turkish or Chinese nutgall.
Carbetapentane, known chemically as, 2-(2-diethylaminoethoxy)ethyl-1 phenylcyclopentane carboxylate is an antitussive compound that is described in U.S. Pat. No. 2,842,585 and is structurally related to caramiphen. Carbetapentane citrate has a melting point of 93° C. and occurs as a white powder freely soluble in water and slightly soluble in alcohol.
Carbetapentane has an atropine-like action that depresses the cough reflex by selective central nervous system depression.
Chlorpheniramine, known chemically as 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine, is a synthetic optically active d-isomer resolved from dl racemates of the amine by treating said racemate with an optically active d- or I-isomer of the substituted succinic acid in the presence of a non-reactive compatible organic solvent to cause the formation of the corresponding diasteroisomeric salts thereof, separating the salts so obtained by fractional crystallization, and releasing the desired d-isomers from the separated amine salts as more fully described in U.S. Pat. No. 3,061,517
Chlorpheniramine maleate salt has a melting point of 130-135° C. and is slightly soluble in benzene and ether.
Antitussive and antihistamine compounds in the form of their free bases as well as their salts, e.g. hydrochloride, citrate, maleate, tannate, etc., are well known. Antitussives and antihistamines in the form of their tannate salts are very desirable because such salts are generally stable and may be combined in such form without any untoward side effects.
Antitussives and antihistamines in the form of their tannate salts are typically prepared by reacting the free base, e.g. carbetapentane, chlorpheniramine, etc. with tannic acid in the presence of a volatile solvent, usually isopropanol. Typically, in the conventional isopropanol route, the antitussive or antihistaminic free base and the tannic acid will be present in the isopropanol at a concentration of about 20% based on the weight of the reaction mixture. The reaction mixture is stirred for about one hour while maintaining the mixture at 60-70° C. The reaction mixture is cooled to room temperature and then filtered, washed with isopropanol and then vacuum dried. Alternative routes to the tannate salts are described in U.S. Pat. Nos. 5,599,846 and 5,663,415.
The Invention
It has now been found that the novel combination of carbetapentane tannate and chlorpheniramine tannate produces a composition having antitussive and antihistaminic properties superior to the use of either one of the tannate compounds alone.
The compositions of the present invention may be prepared for oral administration in the form of powders, capsules, elixirs, syrups and the preferred forms of tablets formulated so that ideally each tablet contains about 50 mg to about 75 mg, preferably about 60 mg of carbetapentane tannate and about 2.5 mg to about 7.5 mg, preferably about 5.0 mg chlorpheniramine tannate or suspensions formulated so that ideally each 5 mL (approximately 1 teaspoon) of suspension would contain approximately 20 to 30 mg carbetapentane tannate preferably about 30 mg of carbetapentane tannate and about 2.0 mg to about 6.0 mg, preferably about 4.0 mg chlorpheniramine tannate.
Tablets containing the unique tannate combination of the present invention are prepared in a conventional manner by the addition of suitable pharmaceutical carriers including fillers, diluents, colorants, lubricants and the like as well as conventional and well known binding and disintegrating agents. A typical tablet composition of the present invention containing starch, dibasic calcium phosphate, coloring, magnesium stearate, methylcellulose, polygalacturonic acid, povidone and talc as described in Example 1 which follows is prepared by well known conventional tabletting techniques such as those disclosed in U.S. Pat. Nos. 3,018,221; 2,798,024 and 2,757,124.
REFERENCES:
patent: 2757124 (1956-07-01), Wolff et al.
patent: 2798024 (1957-07-01), Zapapas et al.
patent: 3018221 (1962-01-01), Millar et al.
patent: 3061517 (1962-10-01), Lewis et al.
patent: 4552899 (1985-11-01), Sunshine et al.
patent: 4601714 (1986-07-01), Burnhill
patent: 5164398 (1992-11-01), Sims et al.
patent: 5559846 (1996-09-01), Tam
patent: 5599846 (1997-02-01), Chopdekar et al.
patent: 5663415 (1997-09-01), Chopdekar et al.
patent: 5807579 (1998-09-01), Vilkov et al.
patent: 6037358 (2000-03-01), Gordziel
patent: 6287597 (2001-09-01), Gordziel
patent: 6306904 (2001-10-01), Gordziel
patent: 6417206 (2002-07-01), Leflein et al.
patent: 6462094 (2002-10-01), Dang et al.
patent: 2001/0011104 (2001-08-01), Gordziel
patent: 39007786 (1964-05-01), None
patent: 64007786 (1993-08-01), None
patent: 06287144 (1995-01-01), None
Histatuss, Drug Launcehs—Luchem—Document No.: 0041022—Pub. Jul. 1991.*
Weiler et al., “Randomized, double blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan in the treatment of allergic rhinits using an acute model,” Annals of Allergy, vol. 64(1): 63-67.
Goldberg et al., “Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders,” Clinical Medicine, vol. 72(9): 1475-1479.
Triple Tannate, Drug Launches (doc. #: 0182701) 5/99.
Tussi-12, Drug Launches (doc. #: 0179128) 3/99.
Tussi-12, Drug Launches (doc. #: 0176901) 12/98.
R-Tannate, Drug Launches (doc. #: 0172212) 8/98.
Triple Tannate, Drug Launches (doc. #: 0163340). 1/98.
Atrohist, Drug Launches (doc. #: 0154800). 5/97.
Gelhist, Drug Launches (doc. #: 015445). 5/97.
Phenatan, Drug Launches (doc. #: 0149758) 1/97.
Triotann, Drug Launches (doc. #: 0136052) 12/95.
Tri-Tannate, Drug Launches (doc. #: 0129566) 6/95.
Ricobin-D, Drug Launches (doc. #: 0129564) 6/95.
Ricobid, Drug Launches (Doc. #: 0129563) 6/95.
Quad-Tuss Tannate, Drug Launches (doc. #: 0127440) 4/95.
Tri-Tannate, Drug Launches (doc. #: 0179121) 3/99.
Tritan, Drug Launches (doc. #: 0144945) 9/96.
Tri-Natan, Drug Launches (doc. #: 0110372) 11/93.
R-Tannate, Drug Launches (doc. #: 0110158) 11/93.
Trin Tuss, Drug Launches (doc. #: 0049139) 3/93.
Tanoral, Drug Launches (doc. #: 0044406) 4/92.
Histatuss, Drug Launches (doc. #: 0041022) 7/91.
Tri-Tannate, Drug Launches (doc. #: 0020282) 9/87.
Tri-Tannate, Drug Launches (doc#: 1002267) 9/97.
Tanoral, Drug Launches (doc#: 1025217) 4/92.
“Robitussin et seq.” Physician's Desk Reference, 33rdEd., 1979, pp. 1424-1425.
Wilson and Grisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, Ninth Ed. 1991, pp. 423 & 425.
D'Addio Alexander D.
Leflein Ronald J.
McIntosh Traviss C.
Medpointe Healthcare Inc.
Olstein Elliot M.
Stauffer Raymond E.
Wilson James O.
LandOfFree
Antitussive/antihistaminic compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitussive/antihistaminic compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitussive/antihistaminic compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3071813